Sermorelin
The Native GHRH Analogue for Diagnostic and Therapeutic Research
Molecular Data
- Formula
- C149H246N56O44S
- Molecular Weight
- 3357.9 g/mol
- Sequence
- Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu…
01
Overview
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was originally FDA-approved for diagnostic testing of GH deficiency and pediatric growth disorders. As a bioidentical fragment of GHRH, it preserves the physiological pulsatile pattern of GH release, distinguishing it from synthetic secretagogues.
02
Mechanism of Action
Sermorelin binds GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate both synthesis and pulsatile release of endogenous GH. Because it relies on intact pituitary function and preserves somatostatin feedback, it maintains the physiological rhythm of GH secretion rather than overriding it.
03
Research Highlights
Clinical diagnostic protocols confirm reliable GH response for deficiency testing
Pediatric growth studies demonstrate sustained IGF-1 elevation with preserved pulsatility
Combination research with GHRP analogues shows additive GH pulse amplitude without feedback disruption
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, once daily at bedtime. FDA-approved for pediatric GH deficiency (historically); research administers before sleep to mimic endogenous GH pulsatility.
Dosage Guidelines
Cycle Length
12 weeks; titration protocols adjust dose based on IGF-1 response.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
Per vial size (typically 1 mL to a 5 mg vial)
Concentration
5 mg/mL (5,000 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
Sermorelin is GRF(1-29) with a short half-life (~10 min). Administer immediately before the target sleep window.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Sermorelin is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Sermorelin Knowledge Graph
Explore how Sermorelin connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Sermorelin — Common Research Questions
What is Sermorelin?
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was originally FDA-approved for diagnostic testing of GH def... Sermorelin belongs to the Weight Loss research category and is studied for its the native ghrh analogue for diagnostic and therapeutic research.
How does Sermorelin work?
Sermorelin binds GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate both synthesis and pulsatile release of endogenous GH. Because it relies on intact pituitary function and preserves somatostatin feedback, it maintains the physiological rhythm of GH secretion rather than overriding it.
What are the key research benefits of Sermorelin?
Bioidentical GHRH fragment — preserves natural GH pulsatility. FDA-approved diagnostic use for GH deficiency. Physiological IGF-1 elevation without supraphysiological peaks. Favorable safety profile in long-term administration. Synergistic with GHRPs for combined GH stimulation. Preserved pituitary sensitivity and feedback regulation.
What is the molecular structure of Sermorelin?
Sermorelin has the molecular formula C149H246N56O44S and a molecular weight of 3357.9 g/mol. Its amino acid sequence is Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about Sermorelin?
Clinical diagnostic protocols confirm reliable GH response for deficiency testing Pediatric growth studies demonstrate sustained IGF-1 elevation with preserved pulsatility Combination research with GHRP analogues shows additive GH pulse amplitude without feedback disruption These findings are based on preclinical and clinical research. Sermorelin is a research compound and these studies do not constitute medical advice.
Is Sermorelin FDA approved?
Sermorelin was previously FDA-approved for diagnostic testing of growth hormone deficiency and pediatric growth disorders. Its approved status has changed over time; consult current FDA databases for the latest information.
What category does Sermorelin belong to?
Sermorelin belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Clinical diagnostic protocols confirm reliable GH response for deficiency testing
Pediatric growth studies demonstrate sustained IGF-1 elevation with preserved pulsatility
Combination research with GHRP analogues shows additive GH pulse amplitude without feedback disruption